Astragalin (Kaempferol 3-O-β-D-Glucopyranoside)
1. Identity: Chemical and Botanical Profile
1.1 Chemical Identity
Astragalin (AG), also known as kaempferol 3-O-β-D-glucopyranoside, has the molecular formula C21H20O11, a molecular weight of 448.38, a melting point of 223°C–229°C, and a boiling point of 823.2°C ± 65.0°C. It belongs to the flavonol subclass of flavonoids—a large family of plant polyphenols—and its structure consists of the aglycone kaempferol with a β-D-glucopyranose sugar unit attached at the 3-position oxygen (hence the systematic name kaempferol 3-O-β-D-glucopyranoside). Astragalin can also be produced in vivo by glycosylation of kaempferol at the 3C-O position. UDP-dependent glycosyltransferases (UGT) were used as biocatalysts in the synthesis of astragalin, and a recombinant strain of Arabidopsis thaliana was used to construct an efficient UDP-glucose synthesis pathway by use of enzymes such as uridylyltransferase, sucrose phosphorylase, and sucrose permease.
1.2 Botanical Sources
Astragalin is a natural flavonoid that can be isolated from a variety of familiar edible plants, such as the seeds of green tea, Morus alba L., and Cuscuta chinensis. Additional primary sources include the leaves of persimmon, horseradish tree (Moringa oleifera) leaves, lotus leaf (Nelumbo nucifera), Chinese rose (Rosa chinensis), and Thesium chinense.
Cuscuta chinensis Lam. is a member of the Convolvulaceae family; the seeds of the genus Cuscuta are a rich source of astragalin and are utilized as a traditional folk medicine to cure osteoporosis in various Asian countries including Pakistan. C. chinensis has high contents of astragalin—29–34% of total phenolics compared to other species.
Cassia alata belongs to the family Fabaceae. The leaves of C. alata are found to be effective against skin diseases including eczema and chronic skin impurities in tropical regions of the world (Malaysia, Brazil, and Indonesia). Astragalin has also been isolated from the plants of Ebenaceae, Rosaceae, and Eucommiaceae families. In the context of Vitis grapes and wine, kaempferol-3-O-glucoside (astragalin) was the major kaempferol derivative identified in grape and thus in wine.
1.3 Common Forms and Preparations
Astragalin is encountered in several forms relevant to research and product development. As an isolated phytochemical, it is available as a purified powder for laboratory and preclinical use. It is also naturally present in aqueous and ethanolic plant extracts used in traditional preparations. Different forms of processing Cuscuta seeds have resulted in differing absorption and bioavailability of astragalin: the Tmax of astragalin in stir-frying Cuscutae Semen (SF-CS) was longer than that in salt-processed Cuscutae Semen (SP-CS), while the Cmax of astragalin in SF-CS was reduced. These findings illustrate that salt-processing enhances the absorption and bioavailability of astragalin via increasing its solubility in rats. Due to the poor water solubility and low bioavailability of astragalin, metabolic engineering technologies such as enzymatic synthesis have been utilized for structural modification, resulting in hydrophilic astragalin galactoside or glucoside derivatives with improved water solubility and oxidative stability, as well as enhanced efficacy in scavenging radicals and inhibiting inflammatory cytokines.
2. Traditional and Historical Use
2.1 Traditional Chinese Medicine
Astragalin is not typically isolated as a single compound in traditional systems; rather, it is consumed as a constituent of whole-plant preparations. Cuscuta chinensis, one of the richest natural sources of astragalin, has found its use as a traditional medicine in China, Korea, Pakistan, Vietnam, India, and Thailand, where it is commonly used as an anti-aging agent, anti-inflammatory agent, pain reliever, and aphrodisiac. In Traditional Chinese Medicine (TCM), Cuscuta chinensis is used as a tonic medicine by practitioners for the treatment of kidney and liver deficiency. The dry seed of Cuscuta chinensis Lam. is used as a tonic and aphrodisiac to nourish the liver and kidneys and to treat impotence and seminal emission; it is also widely used to improve sexual function, prevent and treat cardiovascular diseases, osteoporosis, and senescence, and it possesses reported anti-tumoral, hepatoprotective, and neuroprotective effects.
Astragalin is a type of flavonoid glycoside that is the primary component in several widely used traditional Chinese anti-inflammatory medications in clinical practice. In the TCM framework, Cuscutae Semen (Tu-Si-Zi, the seed of Cuscuta) has been documented in the Chinese Pharmacopoeia as a tonic herb traditionally prepared as a decoction or salt-processed seed extract.
2.2 Traditional Use in Southeast Asia and South Asia
The leaves of Cassia alata, a significant astragalin-containing plant, are found to be effective against skin diseases including eczema and chronic skin impurities in tropical regions of the world, including Malaysia, Brazil, and Indonesia. In these traditions, leaves were typically prepared as poultices or decoctions for topical and internal use. The seeds of the genus Cuscuta are utilized as a traditional folk medicine to cure osteoporosis in various Asian countries including Pakistan.
2.3 Dietary Exposure
Beyond formal medicinal use, astragalin is a constituent of widely consumed foods. It can be isolated from familiar edible plants such as the seeds of green tea, Morus alba L. (white mulberry), and Cuscuta chinensis. Its presence in grapes and wine, green tea, mulberry, lotus, rose, and persimmon means that human populations have had continuous low-dose dietary exposure to this compound throughout history across many cultures.
3. Chemistry: Key Constituents and Structural Features
3.1 Classification Within Flavonoids
Astragalin (kaempferol-3-O-β-D-glucoside) is a bioactive natural flavonoid well known for its medicinal importance. As a flavonol glycoside, its pharmacological activity stems from both its kaempferol backbone—which contributes antioxidant and anti-inflammatory properties through the conjugated ring system and hydroxyl groups—and its glucose moiety, which influences solubility, absorption, and targeting.
Astragalin carries out its pharmacological activities through the regulation and modulation of various molecular targets, including transcription factors (NF-κB, TNF-α, and TGF-β1), enzymes (iNOS, COX-2, PGE2, MMP-1, MMP-3, MIP-1α, SOD, and GPX), kinases (JNK, MAPK, Akt, ERK, SAPK, IκBα, PI3K, and PKCβ2), cell adhesion proteins, apoptotic and anti-apoptotic proteins (Beclin-1, Bcl-2, Bax, Bcl-xL, cytochrome c, LC3A/B, and caspase-3/9), and inflammatory cytokines (SOCS-3, SOCS-5, IL-1β, IL-4, IL-6, IL-8, IL-13, MCP-1, CXCL-1, CXCL-2, and IFN-γ).
3.2 Relationship to Kaempferol
Kaempferol, the aglycone parent of astragalin, is itself a well-characterised dietary flavonol. The attachment of glucose at the C-3 position (forming astragalin) modulates the compound's physical properties significantly: water solubility is increased relative to kaempferol, but bioavailability remains constrained by the molecular weight and susceptibility to metabolic deglycosylation. The bioavailability limitations of astragalin are mainly due to its molecular structure (higher molecular weight and worse water solubility) and its easy conversion by metabolic enzymes such as uridine diphosphate-glucuronosyltransferases (UGTs) in the liver and intestine, which is characterized by rapid absorption and clearance.
4. Pharmacokinetics
4.1 Absorption and Bioavailability
After oral administration, astragalin is absorbed into the bloodstream and circulates freely in the plasma. Its pharmacokinetic parameters are dose-dependent, showing biphasic absorption with an initial rapid phase followed by slower sustained release. The absolute oral bioavailability of astragalin is relatively low, typically around 20–30%.
4.2 Metabolism and Elimination
Astragalin undergoes metabolism primarily through phase II enzymes, such as glucuronidation and sulfation, leading to the formation of water-soluble metabolites that can be easily excreted. The elimination half-life is relatively short, reported at 1 to 3 hours in humans, indicating rapid elimination. Urine is the primary route of excretion for astragalin and its metabolites. UGT enzymes have been reported to be key metabolizing enzymes of astragalin in vivo, including CtUGT3 and AtUGT78D2.
4.3 Distribution
Astragalin is distributed in several organs, with the highest concentration in the gastrointestinal tract. It can also cross the blood-brain barrier and can be detected in the liver, lungs, and kidneys. Particularly, higher concentrations are found in the liver and kidney tissues, indicating that the kidney, liver, and uterus are the core target organs of astragalin distribution.
4.4 Effect of Preparation
Different forms of processing Cuscutae Semen result in differing absorption and bioavailability of astragalin. The Tmax of astragalin in stir-fried seeds was longer than that in salt-processed seeds, while the Cmax was reduced in stir-fried seeds. Salt-processing enhances the absorption and bioavailability of astragalin by increasing its solubility.
Although there are studies that investigated the pharmacokinetics of astragalin, there is a lack of clinical pharmacokinetic validation, and the pharmacological properties in the clinical setting remain to be fully characterised.
5. Mechanisms of Action
5.1 Anti-Inflammatory Mechanisms
Astragalin exerts anti-inflammatory effects by antagonizing the increase of nitric oxide (NO), tumor necrosis factor-α (TNF-α), prostaglandin E2 (PGE2), interleukin (IL)-1β, IL-6, IL-12, IL-13, IL-18, and leukotriene B4 (LTB4) in lipopolysaccharide (LPS) and interferon-γ (IFN-γ)-stimulated RAW264.7 macrophage cells. In LPS-induced mouse macrophage J774A.1 cells, astragalin significantly decreased the pro-inflammatory cytokines TNF-α, IL-1β, IL-6, and chemokine macrophage inflammatory protein-1α (MIP-1α), as well as the gene expression of macrophage chemoattractant protein-1 (MCP-1). Additionally, astragalin downregulated the gene expression and protein synthesis of cyclooxygenase (COX) and inducible nitric oxide synthase (iNOS).
Molecular biology studies have revealed that astragalin regulates complex signaling networks, including NF-κB, MAPK, and JAK/STAT pathways. Specific molecular mechanisms include suppressing inflammation and oxidative stress via targeting the TLR4/NF-κB pathway, alleviating pain via modulating the ERK pathway, inhibiting tumors via the PI3K/AKT, MAPK, and JAK/STAT pathways, ameliorating neuropathy via modulating the HO-1/MAPK, PI3K/Akt, SIRT1, and Notch/HES-1-NF-κB pathways, attenuating respiratory diseases via targeting the TLR4-PKCβ2-NADPH and MAPK pathways, improving osteoarthritis and osteoporosis via mediating the BMP pathway, and treating ulcerative colitis via modulating the NF-κB pathway.
5.2 Antioxidant Mechanisms
Astragalin possesses significant antioxidant activity, scavenging free radicals and protecting against oxidative stress. Its phenolic hydroxyl groups confer direct radical-scavenging capacity. In addition, astragalin upregulates endogenous antioxidant enzyme systems including superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH), as reported across multiple preclinical models.
5.3 Anticancer Mechanisms
Astragalin significantly inhibits the proliferation and migration of cancer cells through induction of apoptosis (by modulation of Bax, Bcl-2, P53, caspase-3, caspase-6, caspase-7, caspase-8, and caspase-9 protein expression) and cell cycle arrest (by modulation of Cyclin D1, Cyclin E, P21, P27, CDK2, and CDK4 protein expression). Moreover, astragalin suppresses cancer cell migration by inhibiting the expression of matrix metalloproteinases MMP-2 and MMP-9. Astragalin affects the proliferation, invasion, and angiogenesis of cancer cells through participating in signaling pathways, regulating apoptotic proteins, inactivating oncogenes and suppressor genes, as well as influencing the tumor microenvironment and angiogenesis.
5.4 Neuroprotective Mechanisms
Astragalin exhibits neuroprotective effects by maintaining cerebral redox homeostasis, reducing neurodegeneration, and enhancing antioxidant enzyme activities. Astragalin activated autophagy and up-regulated the levels of autophagic flux-related proteins in Alzheimer's disease mouse models, and down-regulated the phosphorylation level of PI3K/Akt-mTOR pathway-related proteins, an effect reversed by autophagy inhibitors.
5.5 Procoagulant Activity
Astragalin, isolated from flowers of Rosa chinensis Jacq., possesses anti-inflammatory, antioxidant, antiviral, analgesic, antibacterial, antiallergic, and antihepatotoxic effects. Notably, a distinct and potentially important property has been identified in coagulation biology. Its procoagulant effect was investigated by activated partial thromboplastin time (APTT), thrombin time (TT), prothrombin time (PT), and fibrinogen (FIB) assays in vitro, and by a rat model established using heparin sodium. Results showed that astragalin had good procoagulant effects compared with the control group in vitro, and in the in vivo model astragalin could shorten the coagulation time and significantly increase the number of platelets.
6. Scientific Evidence by Area of Use
Important caveat: The substantial majority of published research on astragalin consists of in vitro cell studies and in vivo animal experiments. There is a lack of clinical pharmacokinetic validation, and the pharmacological properties in the real drug environment in the clinic remain to be fully characterised. No large-scale randomised controlled trials in humans have been published as of the time of this article. All human evidence reviewed below is therefore preliminary. Claims about efficacy in humans should be regarded as unproven pending rigorous clinical investigation.
6.1 Inflammation
Astragalin is a type of flavonoid glycoside that is a primary component in several widely used traditional Chinese anti-inflammatory medications. A literature review covering 2003 to 2023 found that astragalin demonstrates promising anti-inflammatory potential in various models of inflammatory diseases and possesses inhibitory effects on inflammation-related factors and protein levels in various in vitro cell models, such as macrophages, microglia, and epithelial cells.
In vivo studies have shown that astragalin effectively alleviates neuroinflammation and brain damage while also exhibiting potential for treating moderate diseases such as depression and stroke; it also demonstrates significant anti-inflammatory effects on both large and small intestinal epithelial cells. Animal experiments have further demonstrated that astragalin exerts therapeutic effects on colitis mice.
Evidence strength: Predominantly in vitro and in vivo animal data. No human clinical trials have been published. Evidence is mechanistically compelling but clinically unconfirmed.
6.2 Oncology (Anticancer)
Astragalin may exert anticancer effects through anti-inflammatory, anti-glycosylation, anti-adipogenesis, antioxidant, and neuroprotective effects. A review of literature on astragalin and cancer found that it affects the proliferation, invasion, and angiogenesis of cancer cells through participating in signaling pathways, regulating apoptotic proteins, inactivating oncogenes and suppressor genes, as well as the tumor microenvironment and angiogenesis.
In colon cancer, astragalin was evaluated for its inhibitory effect on proliferation and migration of human colon cancer HCT116 cells both in vitro and in vivo. Results showed that astragalin significantly inhibited proliferation and diffusion of HCT116 cells by inducing apoptosis and cell cycle arrest, and suppressed migration by inhibiting MMP-2 and MMP-9 expression. In gastric cancer cells (AGS), studies used dosages of 80 and 160 μM in vitro and 25, 50, and 75 mg/kg via intragastric route in nude mice bearing HCT116 cells.
Astragalin inhibits cell proliferation and accelerates apoptosis in cervical cancer cells by regulating signaling pathways and cellular oxygenation. Network pharmacological analysis has reported that in HeLa cells, astragalin exerts regulatory effects on signaling proteins such as EGFR, STAT3, and cyclin D1, affecting the ErbB and forkhead box protein O signaling pathways.
Evidence strength: Entirely preclinical. Astragalin, with its wide and natural sources, strong anticancer activity, high safety value, and low cost, has potential to be an alternative drug with considerable efficacy in the prevention and treatment of malignant tumors; however, further research is required. No human clinical trials in oncology.
6.3 Bone Health: Osteoporosis and Osteoblast Differentiation
After treatment with astragalin for 4 weeks, bone histomorphometric analysis and micro-CT analysis were used to measure the effect on bone formation. The results found that mineral apposition rate (MAR), bone formation rate (BFR/BS), osteoblast surface (Ob.S/BS), and osteoblast number at the distal femur were significantly increased in astragalin-treated ovariectomised (OVX) mice compared with untreated OVX mice, indicating an increase in bone formation and osteoblast number. These findings were further supported by observed increases in bone mineral density (BMD), bone volume fraction (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N) in astragalin-treated mice.
Astragalin has been reported to show estrogenic activity against osteoporosis and upregulate alkaline phosphatase (ALP) activity in UMR-106 osteoblastic cells. Taken together, these data indicated that astragalin could be used for osteoporosis treatment.
Evidence strength: Animal models (OVX mice) and cell-based studies only. No human randomised controlled trials. Mechanistic rationale is strong; clinical translatability remains unconfirmed.
6.4 Osteoarthritis and Joint Inflammation
Astragalin, as a bioactive flavonoid with anti-inflammatory, antioxidant, and protective properties, provides a potential agent for rheumatoid arthritis (RA). Its therapeutic efficacy was explored using DBA/1J mice with collagen-induced arthritis (CIA). Astragalin was demonstrated to significantly attenuate inflammation in CIA mice, with effects associated with decreased severity of arthritis (based on the arthritis index), joint swelling and reduced bone erosion and destruction. Astragalin treatment suppressed the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-8) and inhibited the expression of matrix metalloproteinases (MMP-1, MMP-3, and MMP-13) in chondrocytes and synovial cells.
Fibroblast-like synoviocytes derived from RA patients (MH7A cells) were applied to verify these effects. While this represents a step toward relevance to human tissue, it remains an in vitro validation rather than a clinical trial.
Evidence strength: Animal models and human-derived cell lines (ex vivo). No clinical trials in rheumatoid arthritis or osteoarthritis patients.
6.5 Gastrointestinal Health: Ulcerative Colitis and Inflammatory Bowel Disease
The therapeutic effects of astragalin were investigated in mice with dextran sulfate sodium (DSS)-induced colitis. Treatment with astragalin reduced weight loss and the disease activity index (DAI), prevented colon shortening, and alleviated colonic tissue damage. Astragalin treatment reduced the expression of pro-inflammatory cytokines and related mRNAs (TNF-α, IL-6, and IL-1β), inhibited colonic infiltration by macrophages and neutrophils, ameliorated metabolic endotoxemia, and improved intestinal integrity.
In human colonic epithelial cells, this study investigated the anti-inflammatory effect of astragalin via blockade of the nuclear factor κB (NF-κB) signaling pathway in human colonic epithelial cells (HCT-116 and HT-29) and a murine colitis model. Cells were pretreated with astragalin and stimulated with tumor necrosis factor-α (TNF-α).
Evidence strength: Preclinical (in vitro human cell lines and murine models). No human clinical trials for ulcerative colitis or IBD.
6.6 Neurodegenerative Disease and Neuroprotection
A study investigated the neuroprotective effect and mechanism of astragalin on APP/PS1 transgenic mice (an Alzheimer's disease model) and Aβ25-35-injured HT22 cells. The results found that astragalin ameliorated cognitive dysfunction, reduced hippocampal neuronal damage and loss, and attenuated Aβ (amyloid-beta) pathology in APP/PS1 mice. Astragalin activated autophagy and up-regulated the levels of autophagic flux-related proteins, and down-regulated the phosphorylation level of PI3K/Akt-mTOR pathway-related proteins.
In ischemia/reperfusion (I/R) brain injury models, the astragalin-treated group demonstrated significantly downregulated mRNA expression levels of inflammatory cytokines compared with the I/R group, indicating that astragalin may regulate inflammatory gene responses in the cerebral ischemia/reperfusion injury model.
Evidence strength: All preclinical (transgenic mouse models, cell culture). No human clinical trials for any neurological condition.
6.7 Diabetes and Metabolic Disorders
Preclinical evidence covers several mechanisms relevant to metabolic disease. Ex vivo investigations used a goat lens model to examine aldose reductase (AR) inhibition by astragalin, and in vivo studies were performed in streptozotocin-induced diabetic rats. In diabetic rats, astragalin improved body weight, blood insulin, and glucose as well as levels of galactitol in a dose-dependent manner, and also suppressed AR activity and altered inflammatory mediators and cytokines.
In a study on diabetic spermatogenic dysfunction, astragalin (3.3, 10, and 30 mg/kg) and clomiphene (5 mg/kg) were orally administered to streptozotocin-induced diabetic male mice for 8 weeks. After the experiments, reproductive organs, sperm parameters, and histomorphological changes were analysed, and antioxidant and anti-inflammatory capacity were estimated in testicular tissues. The results revealed that astragalin significantly improved the reproductive organs, sperm parameters, and testicular morphology to different degrees in diabetic mice.
Concerning glucose regulation, astragalin has been studied for α-glucosidase inhibition and AMPK pathway modulation. Dietary supplementation of natural active products with α-glucosidase inhibitory activity has been proven to be an effective method in controlling hyperglycemia. Astragalin has been reported to exert hypoglycemic effects by both inhibiting α-glucosidase and modulating AMPK signaling.
Regarding obesity, astragalin (3-O-glucoside of kaempferol), isolated from Moringa oleifera leaves, has been found to modulate leptin and adiponectin secretion and inhibit adipogenesis in 3T3-L1 adipocytes.
Evidence strength: Entirely preclinical. No human clinical trials in diabetes, obesity, or metabolic syndrome.
6.8 Cardiovascular and Ischemia/Reperfusion Injury
Astragalin has a wide range of pharmacological activities and possesses therapeutic effects against ischemia/reperfusion injury in preclinical settings. Studies in cardiac models have examined myocardial ischemia/reperfusion injury. These phenomena indicate that different pathological states such as myocardial ischemia/reperfusion injury may affect the metabolism of astragalin in vivo, and the total urine and bile excretion rates of astragalin in a myocardial ischemia/reperfusion injury group were lower than those in the normal group, whereas the fecal excretion rate was higher than the normal group.
Evidence strength: Preclinical only. No clinical cardiovascular trials.
6.9 Respiratory Diseases
Astragalin possesses therapeutic effects in respiratory diseases in preclinical models. Published preclinical studies have examined astragalin in lung injury and allergic airway inflammation models. Previous studies on the anti-inflammatory activity of astragalin in animals have mainly reported the effects on mastitis, endotoxemia, lung injury, and allergic inflammation in mice or rats. The respiratory-relevant mechanisms described in the literature involve the TLR4-PKCβ2-NADPH and MAPK pathways.
Evidence strength: Preclinical only. No human clinical trials in respiratory conditions.
6.10 Coagulation
A study on astragalin isolated from Rosa chinensis examined its procoagulant activity. The procoagulant effect was investigated by APTT, TT, PT, and FIB assays in vitro, and a rat model established by heparin sodium was used to evaluate the mechanism in vivo. Astragalin had good procoagulant effects compared with the control group in vitro, and in the in vivo model it shortened coagulation time and significantly increased platelet numbers. This procoagulant property stands in contrast to the anti-inflammatory context and is an important consideration for safety, discussed below.
Evidence strength: Preliminary preclinical. No human trials. This finding requires further investigation given its potential clinical implications.
7. Dosages Reported in Preclinical Studies
No standardised therapeutic dosage has been established for astragalin in humans. The following dosages are reported from published preclinical research only and cannot be directly extrapolated to humans:
- In colon cancer (HCT116) cell studies, concentrations of 5, 10, 20, 40, 80, and 160 μM were used in vitro; in nude mouse xenograft models, intragastric doses of 25, 50, and 75 mg/kg were studied.
- In studies on diabetic spermatogenic dysfunction, astragalin was orally administered at 3.3, 10, and 30 mg/kg to streptozotocin-induced diabetic male mice for 8 weeks.
- In gastric cancer (AGS) cell studies, concentrations of 80 and 160 μM were used in vitro.
- In the colitis (DSS-induced) murine model, astragalin was administered orally; specific dose ranges in that study were reported in the source literature alongside evaluation of weight loss, disease activity index, and cytokine profiles.
- In the diabetic cataract rat model, astragalin was administered at different dose levels and scrutinized for activity against diabetic cataract.
Further exploration of suitable dosage regimens and adjuvants for astragalin in the treatment of specific diseases is needed, along with further evaluation of specific pharmacological mechanisms and clinical safety.
8. Safety Considerations and Interactions
8.1 General Safety Profile
Astragalin is characterised in the scientific literature as having a high safety value and low cost as a natural product. Across the preclinical studies reviewed, serious acute toxicity has not been prominently reported at the doses studied. Many studies focus on natural active ingredients due to their significant effect and lower side effects. Nevertheless, the absence of reported toxicity in animal models and cell studies does not constitute evidence of clinical safety in humans.
8.2 Procoagulant Activity — a Specific Safety Consideration
A specific and notable safety consideration concerns astragalin's demonstrated procoagulant effects. Studies showed that astragalin had good procoagulant effects in in vitro coagulation assays (APTT, TT, PT, FIB), and in a heparin-anticoagulated rat model, astragalin shortened coagulation time and significantly increased platelet numbers. This suggests a potential risk of enhanced coagulation or thrombosis in susceptible individuals, and warrants particular attention in populations taking anticoagulant medications (such as warfarin or heparin) or those with pre-existing clotting disorders. This finding is preliminary and derived from animal and in vitro models, but represents a biologically plausible interaction requiring human study.
8.3 Dual and Context-Dependent Pharmacological Behaviour
It is noteworthy that astragalin may show opposite pharmacological activities in some specific situations, such as promoting apoptosis in the treatment of tumors while exhibiting anti-apoptotic effects in the treatment of menopausal symptoms and other conditions, suggesting that more in vivo and in vitro studies are needed to elucidate the quantitative-effect relationship of astragalin. This context-dependent behaviour is important when considering its use in complex clinical scenarios.
8.4 Metabolic Enzyme Interactions
Astragalin is easily converted by metabolic enzymes such as UGTs in the liver and intestine, characterised by rapid absorption and clearance. Because UGTs are involved in the metabolism of numerous pharmaceutical drugs, there exists a theoretical potential for metabolic drug interactions—specifically, competition for or inhibition of UGT enzymes that metabolise co-administered drugs. This has been examined in related compounds but has not been specifically characterised for astragalin in human studies.
8.5 Bioavailability Enhancement Strategies and Safety
Improved processing or structural optimisation may enhance gastric absorption and delay metabolism, thereby increasing bioavailability. Nanoformulations, emulsification systems, and semi-synthetic derivatives of astragalin have been explored in preclinical settings; the safety profiles of these modified forms in humans have not been established.
8.6 Absence of Human Clinical Safety Data
Further exploration of suitable dosage regimens and adjuvants for astragalin in the treatment of specific diseases is needed, and the specific pharmacological mechanisms and clinical safety of astragalin also need to be further evaluated. No systematic human safety studies, no published Phase I clinical pharmacology studies, and no formal regulatory assessments of astragalin as an isolated compound were identified in the peer-reviewed literature at the time of this article.
9. Research Status and Outlook
Astragalin has emerged as a research hotspot in recent years due to its outstanding bioactivities and promising therapeutic effects for numerous diseases. The compound has documented pharmacological activities and potential therapeutic effects against cancers, osteoarthritis, osteoporosis, ulcerative colitis, mastitis, obesity, diabetes mellitus, diabetic complications, ischemia/reperfusion injury, neuropathy, respiratory diseases, and reproductive system diseases.
Despite this broad preclinical profile, although researchers have reported multiple pharmacological applications of astragalin in various diseased conditions, further experimental investigations are still mandatory to fully understand its mechanism of action. Critically, the translation of preclinical findings to human clinical trials remains largely absent from the published literature. The field requires pharmacokinetically informed dose-finding studies in humans, followed by randomised controlled trials in the specific disease areas where preclinical evidence is most robust (bone health, inflammatory bowel disease, and metabolic disorders represent the areas of strongest mechanistic rationale).
References
Go back